文献速递冠心病血脂与心血管预防

P2Y12抑制剂与阿司匹林单药用于冠心病二级预防的患者水平荟萃分析

P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

该研究纳入7项随机试验、24,325例确诊冠心病患者,比较P2Y12抑制剂单药与阿司匹林单药用于二级预防的效果。2年随访时,P2Y12抑制剂单药的主要复合终点风险更低(HR 0.88),心肌梗死更少,大出血风险相似,净不良临床事件更低。

要点

  • P2Y12抑制剂单药较阿司匹林降低主要复合终点风险(HR 0.88)。
  • 心肌梗死风险显著降低(HR 0.77),大出血风险相似。
  • 净不良临床事件更低(HR 0.89),亚组与药物类型效应一致。

核心结论

  • 在确诊冠心病患者的长期二级预防中,P2Y12抑制剂单药可能优于阿司匹林单药。

研究设计与样本

  • 随机试验的患者水平荟萃分析,纳入7项试验共24,325例确诊冠心病患者。
  • P2Y12抑制剂组12,178例(氯吡格雷7,545例,替格瑞洛4,633例),阿司匹林组12,147例。
  • 采用1-step法汇总数据,主要终点为心血管死亡、心肌梗死和卒中的复合终点。

主要发现

  • 2年时主要复合终点风险P2Y12抑制剂组低于阿司匹林组(HR 0.88;95%CI 0.79-0.97;P=0.012)。
  • 心肌梗死风险更低(HR 0.77;95%CI 0.66-0.90;P<0.001)。
  • 大出血风险相似(HR 0.87;95%CI 0.70-1.09;P=0.23)。
  • 净不良临床事件更低(HR 0.89;95%CI 0.81-0.98;P=0.020)。
  • 治疗效应在预设亚组和不同P2Y12抑制剂类型间一致。

临床怎么用

  • 对确诊冠心病需长期抗血小板二级预防者,可考虑P2Y12抑制剂单药替代阿司匹林单药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aspirin is the only antiplatelet agent with a Class I recommendation for long-term prevention of cardiovascular events in patients with coronary artery disease (CAD). There is inconsistent evidence on how it compares with alternative antiplatelet agents. OBJECTIVES: This study compared P2Y12 inhibitor monotherapy vs aspirin in patients with CAD. METHODS: We conducted a patient-level meta-analysis of randomized trials comparing P2Y12 inhibitor monotherapy vs aspirin monotherapy for the prevention of cardiovascular events in patients with established CAD. The primary outcome was the composite of cardiovascular death, myocardial infarction, and stroke. Prespecified key secondary outcomes were major bleeding and net adverse clinical events (the composite of the primary outcome and major bleeding). Data were pooled in a 1-step meta-analysis. RESULTS: Patient-level data were obtained from 7 trials. Overall, 24,325 participants were available for analysis, including 12,178 patients assigned to receive P2Y12 inhibitor monotherapy (clopidogrel in 7,545 [62.0%], ticagrelor in 4,633 [38.0%]) and 12,147 assigned to receive aspirin. Risk of the primary outcome was lower with P2Y12 inhibitor monotherapy compared with aspirin over 2 years (HR: 0.88; 95% CI: 0.79-0.97; P = 0.012), mainly owing to less myocardial infarction (HR: 0.77; 95% CI: 0.66-0.90; P < 0.001). Major bleeding was similar (HR: 0.87; 95% CI: 0.70-1.09; P = 0.23) and net adverse clinical events were lower (HR: 0.89; 95% CI: 0.81-0.98; P = 0.020) with P2Y12 inhibitors. The treatment effect was consistent across prespecified subgroups and types of P2Y12 inhibitors. CONCLUSIONS: Given its superior efficacy and similar overall safety, P2Y12 inhibitor monotherapy might be preferred over aspirin monotherapy for long-term secondary prevention in patients with established CAD. (P2Y12 Inhibitor or Aspirin Monotherapy as Secondary Prevention in Patients With Coronary Artery Disease: An Individual Patient Data Meta-Analysis of Randomized Trials [PANTHER collaborative initiative]; CRD42021290774).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Gragnano F, Cao D, Pirondini L, et al. P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. J Am Coll Cardiol. 2023. PMID: 37407118. doi:10.1016/j.jacc.2023.04.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。